Can a Two-Drug punch wake up 'Cold' tumors?

NCT ID NCT05000294

First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether adding tivozanib (a drug that targets blood vessel growth) to atezolizumab (an immunotherapy) can help the immune system attack cancers that normally resist immunotherapy. The trial includes people with several cancer types like bile duct, pancreatic, prostate, and ovarian cancer. Researchers will check if the combination shrinks tumors and how long it keeps them from growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Atezolizumab (Tecentriq) and tivozanib (Fotivda)
What this could lead to
If it works, this could offer a new treatment option for several hard-to-treat cancers that don't respond to immunotherapy alone.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply broadly. The combination may cause side effects like high blood pressure or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILE DUCT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Florida

    RECRUITING

    Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.